Business Context and Reporting Period
This Form 8-K is filed by Cyclacel Pharmaceuticals, Inc. (CYCC) on March 27, 2024. The report addresses a regulatory notice received from The Nasdaq Stock Market regarding the company's compliance with listing standards.
Key Financial Metrics
The filing discloses specific equity data but does not provide revenue, profit, cash flow, or debt figures.
- Stockholders' Equity: $607,000 as of December 31, 2023.
- Nasdaq Minimum Requirement: $2.5 million.
- Compliance Status: Non-compliant with Nasdaq Listing Rule 5550(b)(1).
Material Changes and Events
The primary event is the receipt of a delisting notice due to stockholders' equity falling below the $2.5 million threshold. There is no immediate effect on the listing; the common stock continues to trade under the symbol "CYCC" on the Nasdaq Capital Market.
Outlook, Management Commentary, and Risks
Management is currently reviewing options to address the noncompliance. The company expects to submit a plan to the Nasdaq Listing Qualifications Staff by May 10, 2024. If the plan is accepted, the company may receive an extension of up to 180 calendar days to regain compliance. Failure to timely regain compliance will result in the delisting of the common stock from Nasdaq.
Investor Verification Checklist
- Verify the company's plan submission status by the May 10, 2024 deadline.
- Monitor for any updates regarding the acceptance of the compliance plan or potential appeals to a Nasdaq hearings panel.
- Review subsequent filings for details on capital raising or other actions taken to increase stockholders' equity above $2.5 million.
- Confirm the continued trading status of CYCC on the Nasdaq Capital Market.